Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an announcement.
Genflow Biosciences Plc has filed a request for the examination of its patent application for SIRT6 Variants aimed at treating Non-Alcoholic Steatohepatitis (NASH) in China. This move strengthens Genflow’s global intellectual property portfolio and underscores its commitment to developing innovative therapies for NASH, a severe liver disease with limited treatment options. The filing in China, one of the largest healthcare markets, marks a significant step in protecting Genflow’s technology and advancing SIRT6-based therapies, potentially transforming the treatment landscape for NASH.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on pioneering gene therapies to slow the aging process. Their lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, showing promising preclinical results. The company is conducting a proof-of-concept clinical trial in aged dogs and plans further trials for treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 6,535,833
Technical Sentiment Signal: Hold
Learn more about GENF stock on TipRanks’ Stock Analysis page.